Blood pressure management

A systolic blood pressure of 135 is "normal" in most clinics and not normal at all in biology. The damage to small arteries and microvessels in the heart, brain, and kidneys is continuous with pressure — and the cleanest evidence for aggressive control (SPRINT in over 9,000 high-risk adults) showed 27% lower all-cause mortality at the intensive target. The 2025 AHA/ACC guideline now formalises that lower number. The home-monitoring protocol matters more than the clinic visit, the isometric wall squat is one of the cheapest interventions in the field, and the drug class that's been quietly outperforming on long-term mortality is the angiotensin receptor blocker — not the older angiotensin-converting-enzyme inhibitor it was modelled to imitate.

Blood pressure sits among the most heavily evidenced and most underused longevity levers. It is the single most prevalent modifiable risk factor for cardiovascular disease, stroke, chronic kidney disease, and dementia worldwide. The major guidelines updated between 2024 and 2025 codified two changes that together reshape midlife preventive care: a more aggressive treatment target (closer to 130/80 mm Hg for most adults, with consideration of <120 in the highest-risk), and an explicit shift away from one-off clinic measurements toward structured home-based monitoring. The pharmacology has also been clarified — single-pill combinations are now first-line, angiotensin receptor blockers (ARBs) appear to outperform angiotensin-converting-enzyme (ACE) inhibitors on hard outcomes, and the decade-long claim that night-time dosing reduces cardiovascular events has been definitively settled in the negative. This article walks the modern framework.

Why blood pressure matters the way it does

The relationship between blood pressure and downstream disease is log-linear and continuous — there is no biological threshold below which higher pressure becomes harmless. Damage begins at pressures well below the traditional hypertension cutoff. The reason is mechanical: every heartbeat propagates a pressure wave through arteries that were designed to be elastic and compliant. Sustained pressure stiffens them, fragments their elastin fibres, replaces them with rigid collagen, and bounces the pressure wave back to the heart earlier in the cycle. The downstream consequences are microvascular damage in the heart (driving heart failure with preserved ejection fraction), the brain (driving small-vessel disease and the cerebral white-matter lesions that precede vascular dementia), and the kidneys (driving chronic kidney disease).

Treating blood pressure isn't just about preventing strokes and heart attacks. It's the single most consistent modifiable lever for preserving cognitive function into late life — see Dementia prevention.

SPRINT and the case for aggressive targets

The SPRINT (Systolic Blood Pressure Intervention Trial) trial randomised 9,361 adults aged 50 and older at high cardiovascular risk (excluding those with diabetes or prior stroke) to either intensive systolic blood pressure (SBP) control aiming below 120 mm Hg, or standard control aiming below 140 mm Hg.^[1] The trial was stopped early at a median 3.3 years because the intensive-treatment arm produced:

25% lower major cardiovascular events
27% lower all-cause mortality

The adverse-event signals — orthostatic hypotension, syncope, acute kidney injury — were real but the numbers needed to harm were large (around 500 to over 3,000 depending on the event). Injurious falls did not differ between arms even in adults aged 85 and older, dispelling the older worry about aggressive control in the elderly.^[2]

One critical post-trial observation: when participants returned to usual care, their blood pressure drifted back up, and the survival advantage began to wane 2–4 years after the trial ended.^[3] Blood pressure control is not a finite intervention. It requires sustained lifelong management.

SPRINT-MIND: cognition and dementia

The SPRINT-MIND sub-study followed the same participants for cognitive outcomes. The original 2019 analysis showed a 19% reduction in mild cognitive impairment in the intensive arm, with the composite of mild cognitive impairment and probable dementia down by 15%.^[4] MRI substudies confirmed the biological plausibility: intensive control produced smaller increases in white-matter-lesion volume (a marker of cerebral small-vessel disease) and higher cerebral blood flow.^[5]

Extended 7-year follow-up published in early 2025 confirmed the durability of the cognitive benefit even after participants returned to usual care.^[6] Aggressive blood-pressure control in late midlife appears to permanently alter the trajectory of cerebral small-vessel disease.

What the 2024/2025 guidelines actually say

The 2025 American Heart Association / American College of Cardiology guideline and the 2024 European Society of Cardiology / European Society of Hypertension guideline converged on aggressive targets for most adults.^[7]^[8]

Category	AHA / ACC 2025	ESC / ESH 2024
Normal	<120/80 mm Hg	Similar
Elevated	120–129 / <80	"High normal" 130–139 / 85–89
Stage 1 hypertension	130–139 / 80–89	≥140/90
Stage 2 hypertension	≥140/90	Simplified (single threshold)
General treatment target	<130/80 (lower if very high risk)	120–129 systolic (if well tolerated)

The 2025 US guideline retired the older Pooled Cohort Equations in favour of the PREVENT (Predicting Risk of Cardiovascular Disease Events) calculator, which incorporates kidney function (estimated glomerular filtration rate), body mass index, and optionally HbA1c, urine albumin-to-creatinine ratio, and a Social Deprivation Index. It also removes race as a biological predictor. Drug therapy is recommended whenever the 10-year PREVENT risk is ≥7.5%, or in the presence of cardiovascular disease, chronic kidney disease, or diabetes.

The J-curve and elderly patients

In some older cohorts, blood pressures below 120 mm Hg associate with higher mortality — the J-shaped curve. The current interpretation is that most of this signal is reverse causation: frailty, undiagnosed cancer, advanced heart failure, and malnutrition lower blood pressure while independently raising mortality.^[9] In robust older adults without frailty, treating to <130 mm Hg still cuts cardiovascular death by roughly 45%. The practical implication: aggressive targets for healthy older adults, with relaxed targets for the frail, symptomatic, or those with limited life expectancy.

Measurement: the diagnosis runs on out-of-office monitoring

A single clinic reading is a poor surrogate for the pressure organs actually live under. The 2024 / 2025 guidelines elevate home blood-pressure monitoring (HBPM) or ambulatory blood-pressure monitoring (ABPM) to Class I recommendations — both for diagnosis and for ongoing management.

Two clinically critical phenotypes

The mismatch between clinic and home blood pressure produces two patterns that dramatically alter risk:

White-coat hypertension — clinic readings elevated (≥130/80), home readings normal. Affects 15–30% of adults with elevated clinic readings. Once dismissed as benign anxiety, now documented to carry ~38% higher cardiovascular risk and ~33% higher all-cause mortality versus true normotensives, with about 43% progressing to sustained hypertension within a decade.^[10]
Masked hypertension — clinic readings normal, home readings elevated. The far more dangerous pattern, affecting 10–18% of adults. People look fine in the clinic and walk around unmedicated with cardiovascular risk roughly equivalent to sustained hypertension — about a doubling of cardiovascular mortality and stroke.

Detecting either phenotype requires structured out-of-office measurement. The 2024 ANTI-MASK trial confirmed that treating masked hypertension produces measurable improvements in target-organ damage markers; ignoring it doesn't.

The home BP protocol that produces usable data

For diagnosis or treatment titration, the protocol that the 2025 guidelines codify:^[11]

Device. A validated automated upper-arm (brachial) cuff. Wrist and finger monitors are unreliable. Check the device against the AMA Validated Device Listing or STRIDE BP register.
Conditioning. No caffeine, tobacco, or vigorous exercise for 30 minutes beforehand. Empty bladder.
Posture. Seated, back supported, feet flat on the floor, legs uncrossed. Arm supported on a flat surface at heart level. Silent — talking adds up to 10 mm Hg to systolic readings.
Rest. Five full minutes of quiet sitting before the first reading.
Schedule. Twice daily — morning (after waking and urinating, before breakfast, before morning medications) and evening (before dinner or bedtime).
Duration. Seven consecutive days at minimum (five at absolute minimum).
Per session. 2–3 readings 1–2 minutes apart.
Averaging. Discard everything from day 1 (acclimation effect). Average the rest.

Cuffless wearables: not yet

Smartwatches and biosensor patches that estimate blood pressure optically (photoplethysmography plus pulse-transit-time algorithms) are appealing for continuous monitoring — they could capture nocturnal dips and morning surges that even a 7-day home protocol misses. The 2024 ESC and 2025 AHA / ACC guidelines explicitly recommend against their routine clinical use for now.^[12] The current generation depends on periodic cuff-based calibration, drifts over time, and lacks the standardised validation that brachial cuffs have. They're an interesting trend tool; they aren't a diagnostic substitute yet.

Vascular age: pulse wave velocity and pulse pressure

Brachial blood pressure is a peripheral surrogate for what's actually happening at the central aorta and the microvasculature of the heart, brain, and kidneys. Two metrics provide complementary insight into the underlying biology.

Carotid-femoral pulse wave velocity (cfPWV) measures how fast the pressure wave travels down the aorta — a direct readout of aortic stiffness. Compliant young aortas absorb the systolic ejection (the Windkessel effect) and slow the wave. Stiff aged aortas transmit it fast, and the reflected wave returns to the heart during systole rather than diastole, amplifying central systolic pressure and reducing coronary perfusion. PWV correlates with all-cause mortality independently of standard risk factors and is the closest single thing to a "vascular age" measurement.^[13]

Pulse pressure — the difference between systolic and diastolic (a reading of 120/80 has a pulse pressure of 40) — is a quick, clinical surrogate for the same biology. A widening pulse pressure in midlife and beyond (rising systolic, falling diastolic) is the visible signature of accumulating aortic stiffness, and independently predicts cardiovascular events.

These aren't routine clinical metrics yet, but they're the direction sophisticated preventive cardiology is moving in. The intervention list for stiffening arteries overlaps almost entirely with the rest of this site — aerobic fitness (VO₂ max, zone 2 training), Mediterranean-pattern eating, and the pharmacological levers below.

Sodium sensitivity is a real phenotype, not a universal recommendation

The classic public-health message — eat less salt — is roughly right at the population level. The individual biology is heterogeneous. Salt sensitivity of blood pressure affects about half of adults with hypertension and roughly a quarter of apparently normotensive adults.^[14] In salt-sensitive individuals, even modest sodium intake produces measurable blood pressure rises, and they progress to sustained hypertension years faster than salt-resistant peers (the 15-year Olivetti Heart Study found 88% of salt-sensitive normotensives developed hypertension versus 50% of salt-resistant).^[15] The phenotype also tracks with non-dipping nocturnal BP, insulin resistance, left-ventricular hypertrophy, and heart failure with preserved ejection fraction.

There's also an opposite phenotype — inverse salt sensitivity — affecting roughly 10–15% of adults, in whom severe sodium restriction paradoxically raises blood pressure by activating the renin-angiotensin and sympathetic systems.

Identifying salt sensitivity in routine practice is hard — the gold-standard diagnostic protocols (week-long controlled high-sodium and low-sodium phases, or rapid in-patient saline-and-furosemide challenges) are not widely available. The practical workaround that the 2025 guidelines now endorse strongly:

Aim for <1,500 mg sodium per day in adults with documented hypertension, African-American ancestry, advanced age, or metabolic syndrome.
Use potassium-enriched salt substitutes (NaCl partially replaced with KCl). Now a Class I recommendation. The Salt Substitute and Stroke Study showed a substantial stroke and all-cause mortality reduction.
The dietary-sodium harm is concentrated in packaged and restaurant foods, not the salt shaker — see Foods to limit.

Pharmacology: four classes, single-pill combinations, ARB-leaning

When lifestyle alone can't sustainably keep blood pressure below the target, the modern approach starts with a single-pill combination of two first-line agents from different classes, rather than monotherapy titration. This produces faster goal achievement, better adherence, and avoids the counter-regulatory escape that monotherapy provokes. The four first-line classes:

Angiotensin receptor blockers (ARBs) — losartan, telmisartan, valsartan, candesartan. Block the angiotensin II receptor.
Angiotensin-converting-enzyme inhibitors (ACE inhibitors) — enalapril, lisinopril, ramipril, perindopril. Block conversion of angiotensin I to angiotensin II.
Dihydropyridine calcium channel blockers — amlodipine. Direct vasodilator.
Thiazide / thiazide-like diuretics — chlorthalidone, indapamide.

ARBs are quietly outperforming ACE inhibitors

For decades, ACE inhibitors and ARBs were treated as clinically interchangeable, with ACE inhibitors preferred on cost. Recent large multi-database target-trial-emulation studies have shifted that picture. In head-to-head analyses across UK Biobank and Chinese cohorts, starting on an ACE inhibitor was associated with roughly 12–13% higher all-cause mortality versus starting on an ARB, with a similar excess in major adverse cardiovascular events.^[16] ARBs also produce specific survival benefit in metabolic dysfunction-associated steatotic liver disease that ACE inhibitors don't.^[17] Combined with the better side-effect profile — ARBs essentially don't cause the bradykinin-mediated dry cough or the rare-but-serious angioedema seen with ACE inhibitors — the modern preference for ARBs in the absence of a specific indication for ACE inhibition is increasingly defensible.

The geroprotective angle

Angiotensin II at the AT1 receptor doesn't only raise blood pressure; chronic activation drives mTOR (the master anabolic kinase whose chronic activation accelerates aging), upregulates inflammation through NF-κB, and suppresses the catabolic AMP-activated protein kinase (AMPK) — see Hallmarks of aging and Protein. Blocking the system pharmacologically reverses each of those signals, in a way that mimics the molecular profile of caloric restriction.^[18] Animal models from Drosophila through mice show RAAS blockade extending lifespan; whether the same is true in humans is unproven, but it adds a non-haemodynamic argument for ARBs as a preferred class in the longevity frame.

Chronotherapy: settled in the negative

For roughly a decade, the Spanish MAPEC and Hygia Chronotherapy trials drove an international wave of "take your BP medication at bedtime" guidance, claiming a 45–50% reduction in cardiovascular death from bedtime versus morning dosing. The effect sizes were biologically implausible — far larger than the actual difference in 24-hour blood pressure between the two groups — and prompted multiple large rigorous replication trials.

Both replication trials — the UK TIME trial in over 21,000 participants and the Canadian BedMed trial in over 3,300 — published between 2022 and 2025, found no difference in major cardiovascular events, heart attacks, strokes, or all-cause mortality between morning and bedtime dosing.^[19] A 2024 meta-analysis confirmed the null. The optimal time to take blood-pressure medication is whatever time of day produces the highest adherence — for most people, that's whenever they reliably remember.

Lifestyle: isometric exercise is the underrated finding

The standard lifestyle interventions for blood pressure are well-known — DASH-pattern diet, weight loss, alcohol reduction, regular aerobic activity. A 2023 British Journal of Sports Medicine network meta-analysis of 270 randomised trials in over 15,000 participants reshuffled the priority list.^[20] Across exercise modalities (aerobic training, dynamic resistance, combined training, high-intensity intervals, isometric training), the largest single effect on resting blood pressure came from isometric exercise — sustained static muscle contraction without movement.

The headline result: isometric exercise reduced systolic blood pressure by 8.2 mm Hg and diastolic by 4.0 mm Hg on average — roughly double the effect of aerobic training, and comparable to a typical antihypertensive medication.

Within isometric protocols, the isometric wall squat scored highest. The validated protocol:

Stand with your back against a wall and slide down until your thighs are at a 5–8/10 perceived effort (knee angle typically between 95° and 135°).
Hold the position for 2 minutes.
Rest for 1–4 minutes.
Repeat for 4 sets per session.
3 sessions per week.

Mechanism: the brief local blood-flow occlusion during the held contraction is followed by a sharp reactive hyperaemia that stimulates endothelial nitric oxide synthase and improves vasodilation systemically.^[21] The 2024 / 2025 guidelines integrated isometric training into front-line recommendations alongside aerobic exercise. The combination should be additive.

Other foundational interventions remain critical and roughly co-equal:

Mediterranean / DASH-pattern eating (see Dietary patterns). DASH alone produced ~11 mm Hg systolic reduction in hypertensives in the original trial.
Aerobic and resistance exercise (VO₂ max, Zone 2, Resistance training).
Adequate dietary fibre (>28 g/day for women, >38 g/day for men) — gut microbes ferment fibre into short-chain fatty acids that lower BP.
Weight reduction in overweight adults — every 1 kg of weight loss produces roughly 1 mm Hg of systolic reduction.
Alcohol restriction. See Alcohol — minimum-risk dose is near zero; even moderate intake raises BP measurably.
Sleep quality, particularly screening and treating obstructive sleep apnea, which is the most consistent treatable cause of resistant hypertension.
Stress management (Stress).

Practical guidance

Know your number — at home, not just at the clinic. Get a validated upper-arm cuff. Run the 7-day morning-and-evening protocol; discard day 1; average the rest. The home average is what you act on.
Treat target organs, not just numbers. For most healthy midlife adults, aim for a home-average <130/80 mm Hg. Consider <120 systolic if you're at high cardiovascular risk and tolerate it without orthostatic symptoms. Relax targets for the frail or in advanced age with significant comorbidity.
Screen for masked hypertension. If you have any risk factor (family history, metabolic syndrome, sleep apnea, kidney disease) and your clinic BP runs at the upper end of normal, run a 7-day home protocol. The diagnostic yield is high enough to justify the effort.
If you need medication, ask about a single-pill combination first. ARB + amlodipine or ARB + thiazide are common starting combinations and produce faster control with better adherence than titrating monotherapy.
Take it whenever you reliably remember. The chronotherapy claim is dead; adherence is what matters.
Add the wall squat protocol. 4 × 2-minute sustained holds, 3 times per week, for an average ~8 mm Hg systolic reduction. Zero equipment.
Use potassium-enriched salt substitutes if you have hypertension or are at risk — Class I 2025 recommendation. Most of your sodium comes from processed and restaurant food anyway; cut packaged food first.
Screen for obstructive sleep apnea if your hypertension is resistant to two or three drugs, you snore, you have atrial fibrillation, or you're overweight. See Sleep-disordered breathing.
Treat aggressively in midlife specifically. The cognitive-protection signal from SPRINT-MIND is durable but only if control starts well before symptoms appear.

What's overrated

Cuffless smartwatch BP readings as diagnostic. Useful for trends; not yet a substitute for a validated cuff. The 2024 / 2025 guidelines explicitly say not to use them clinically.
Bedtime dosing of antihypertensives as a survival strategy. Settled by TIME and BedMed. Whatever time gets you to take the pill.
One-off clinic readings as the diagnostic basis. Misses both white-coat and masked hypertension, and the latter has a roughly doubled cardiovascular mortality.
Aggressive sodium restriction in adults who aren't salt-sensitive. A reasonable target (~2 g/day) and potassium replacement matter much more than the extreme end of the curve.
Switching from an ARB to an ACE inhibitor on cost alone. The mortality signal favours the ARB.